Resistant urinary tract infections: Super combination – DocCheck

In the case of resistant urinary tract infections, only antibiotics usually help. Scientists have now found that a combination of the two preparations is particularly effective in resistant cases.

Urinary tract infections in children, pregnant women and men are considered complicated cases that should be treated quickly and effectively. Even in patients who have predisposing risk factors, infections such as cystitis or pyelonephritis can lead to urinary retention or chronic inflammation. Cephalosporin antibiotics such as cefepime are often prescribed for therapy.

alt vs. Nope

In the study, the research team compared different treatment methods that are used for complicated urinary tract infections. A new drug combination has been shown to be particularly effective in stubborn drug-resistant infections: The combination of cefepime and enmetazobactam, a beta-lactamase inhibitor, scored well in both complicated urinary tract infections and acute pyelonephritis.

Great success

The study compared the treatment outcomes of patients receiving conventional piperacillin and tazobactam therapy with another group receiving a new combination of cefepime and enmetazobactam. The result: most of the patients who received the new drug were considered clinically cured after treatment, while only half of the patients who received the standard therapy completely cleared the infection.

Effective against ESBL

It was striking that the new drug duo especially helped patients suffering from ESBL infection – a particularly resistant form of urinary tract infection caused by ESBL (extended-spectrum beta-lactamase)-producing bacteria and often not effectively killed by penicillins and cephalosporins. The cefepime-enmetazobactam combination achieved rapid success in almost 75% of cases.

Guaranteed correctly portioned and without a prescription – this is our new product in the pharmacy channel mortar sign.
aftermath

‚ÄúThis new antibiotic was better than the standard therapy. It is a promising treatment option,” comments the author of the study, Prof. Keith Kaye. “We were looking for antibiotics that would be effective against resistant bacteria like ESBL, and we found the new duo to be highly effective,” says Kaye. He and his team now want to seek approval for the combination.

This text is based on a Rutgers University press release. The original publication can be found here.

Image credit: Andres Hernandez, unsplash.

Leave a Comment